tiprankstipranks
TipRanksStock Market NewsRCUS NewsMizuho Securities Thinks Arcus Biosciences’ Stock is Going to Recover
Blurbs

Mizuho Securities Thinks Arcus Biosciences’ Stock is Going to Recover

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUSResearch Report), with a price target of $51.00. The company’s shares closed last Monday at $21.50, close to its 52-week low of $21.15.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.6% and a 33.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $62.80, a 197.6% upside from current levels. In a report issued on May 2, Berenberg Bank also maintained a Buy rating on the stock with a $68.00 price target.

See the top stocks recommended by analysts >>

Arcus Biosciences’ market cap is currently $1.54B and has a P/E ratio of 50.63.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Read More on RCUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More